Crossmark

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?

Crossref DOI link: https://doi.org/10.1007/s12325-021-02007-y

Published Online: 2022-01-13

Published Print: 2022-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fontes-Sousa, Mário https://orcid.org/0000-0003-0337-3251
Magalhães, Helena https://orcid.org/0000-0002-3815-0640
Oliveira, Alicia https://orcid.org/0000-0003-0833-0736
Carneiro, Filipa

dos Reis, Filipa Palma https://orcid.org/0000-0002-9696-1759
Madeira, Pedro Silvestre https://orcid.org/0000-0002-5184-4671
Meireles, Sara https://orcid.org/0000-0002-9861-7986
License Information

Text and Data Mining valid from 2022-01-13

Version of Record valid from 2022-01-13
More Information

Article History

Received: 7 October 2021

Accepted: 26 November 2021

First Online: 13 January 2022